Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan

Abstract Introduction Respiratory syncytial virus (RSV) is one of the major causes of respiratory tract infections among children. Until recently, the monoclonal antibody palivizumab was the only RSV prophylaxis available in Japan. In 2024, the bivalent RSV prefusion F protein-based (RSVpreF) vaccin...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Naruhiko Ishiwada, Rina Akaishi, Yasuhiro Kobayashi, Kanae Togo, Naohiro Yonemoto, Moe Matsuo, Shinnosuke Kaneko, Amy W. Law, Kazumasa Kamei
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2024-06-01
coleção:	Infectious Diseases and Therapy
Assuntos:	Cost-effectiveness analysis Japan Palivizumab Respiratory syncytial virus RSVpreF Vaccination
Acesso em linha:	https://doi.org/10.1007/s40121-024-01000-6
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!